Gilead Sciences, Inc.

https://www.gilead.com/

Gilead Sciences, Inc. is an American research-based biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines for life-threatening diseases. Headquartered in Foster City, California, the company's mission is to deliver transformative therapeutics that create a healthier world for all people.

Historically, Gilead has been a leader in antiviral therapies, particularly for HIV/AIDS, viral hepatitis (B and C), and influenza, including its significant contributions to COVID-19 treatments. Key products include HIV treatments like Biktarvy, Descovy, and Truvada, hepatitis therapies such as Epclusa and Harvoni, and the COVID-19 antiviral Veklury. In recent years, Gilead has strategically expanded its focus into oncology and inflammation, developing products like Yescarta, Tecartus, and Trodelvy for various cancers.

Led by Chairman and CEO Daniel O'Day, Gilead continues to advance its robust pipeline, which included 58 clinical-stage programs as of April 2025. Recent notable developments include the FDA's acceptance and priority review of a new once-daily HIV regimen (bictegravir plus lenacapavir) in April 2026, and the completion of the acquisition of Arcellx, enhancing its multiple myeloma CAR T cell therapy program. The company also received FDA approval for Yeztugo (lenacapavir), a twice-yearly injectable for HIV prevention, in 2025 and is investing $11 billion through 2030 to strengthen its U.S. manufacturing and R&D capabilities. Gilead aims to deliver over 10 transformative therapies by 2030, reinforcing its market position in critical therapeutic areas.

Latest updates

Gilead Executives to Address Investors at Key Healthcare Conferences

Event summary

  • Gilead Sciences executives will present at four investor conferences in May and June 2026.
  • Presentations will occur at the BofA Securities, RBC Capital Markets, Bernstein, and Goldman Sachs healthcare conferences.
  • Webcasts of the presentations will be available at investors.gilead.com, with replays accessible for 30 days.
  • The conferences span a three-week period, beginning May 12th and concluding June 9th.

The big picture

Gilead's consistent investor conference participation signals a continued effort to manage market expectations and maintain investor confidence. These presentations serve as key touchpoints for analysts and investors to assess the company's strategic direction and financial health amidst ongoing industry consolidation and pricing pressures. The timing of these conferences, clustered within a short timeframe, suggests a concentrated effort to proactively address investor concerns.

What we're watching

Pipeline Progress
The conferences will likely be scrutinized for updates on Gilead’s oncology pipeline, given the ongoing need to diversify revenue streams beyond its established antiviral franchises.
Competitive Landscape
Management commentary regarding competition in the viral hepatitis and HIV markets will be closely watched, particularly as generic erosion continues to impact revenue.
Financial Outlook
The presentations will reveal the extent to which Gilead can sustain its current valuation, given the anticipated impact of patent expirations and the need for continued innovation.

Gilead Secures Priority FDA Review for Novel HIV Treatment

Event summary

  • Gilead submitted a New Drug Application (NDA) to the U.S. FDA for bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN), a once-daily HIV treatment.
  • The FDA granted the NDA a Priority Review designation, setting a PDUFA action date of August 27, 2026.
  • Phase 3 trials (ARTISTRY-1 and ARTISTRY-2) demonstrated comparable efficacy to existing treatments and generally good tolerability.
  • ARTISTRY-1 enrolled the largest study population in a Phase 3 HIV treatment trial to date, and data showed improvements in lipid parameters and treatment satisfaction.

The big picture

Gilead’s move to combine bictegravir with lenacapavir represents a strategic effort to address evolving patient needs and combat potential resistance to existing HIV therapies. The priority review designation signals the FDA’s recognition of the potential clinical benefit, but the crowded HIV treatment market necessitates a differentiated offering to gain significant market share. This development underscores the ongoing need for innovation in HIV treatment, particularly as patients remain on therapy for extended periods.

What we're watching

Regulatory Risk
The FDA’s approval decision in August 2026 will hinge on a full review of the Phase 3 data, and any unexpected safety concerns could delay or deny approval.
Market Adoption
The success of BIC/LEN will depend on its ability to displace Biktarvy and other established treatments, requiring a compelling value proposition for patients and physicians.
Long-Term Data
Longer-term data on BIC/LEN’s efficacy and safety, particularly regarding resistance development and impact on comorbidities, will be crucial for sustained market uptake.

Gilead Consolidates Cell Therapy Ambitions with $7.8 Billion Arcellx Acquisition

Event summary

  • Gilead Sciences completed its acquisition of Arcellx for approximately $7.8 billion, including a $115 per share cash payment and a contingent value right (CVR) of $5 per share.
  • The acquisition grants Gilead full control of anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR T-cell therapy for multiple myeloma, previously developed in collaboration with Arcellx.
  • Arcellx has been delisted from the Nasdaq Global Select Market and now operates as a wholly owned subsidiary of Gilead.
  • The CVR, valued at $6.0 billion in cumulative global net sales by the end of 2029, will be paid out upon achievement of that sales threshold.

The big picture

Gilead’s acquisition of Arcellx underscores the ongoing consolidation within the cell therapy space, as larger players seek to control promising pipeline assets and capture market share. The $7.8 billion price tag reflects the significant potential of CAR T-cell therapies in treating multiple myeloma, a market with substantial unmet need. The contingent value right structure introduces a unique element, tying a portion of the acquisition’s return to anito-cel’s commercial performance.

What we're watching

Execution Risk
The integration of Arcellx and anito-cel into Kite Oncology will be critical; any missteps could delay the therapy’s commercial launch and impact Gilead’s oncology portfolio.
Regulatory Approval
The FDA approval timeline for anito-cel will dictate the speed at which Gilead can realize the acquisition’s potential and the likelihood of achieving the CVR payout.
Commercial Adoption
The success of anito-cel will depend on its ability to demonstrate superior efficacy or safety compared to existing multiple myeloma therapies, influencing its market share and ultimately, the CVR payout.

Gilead Nears Arcellx Acquisition as Tender Offer Extended

Event summary

  • Gilead Sciences has secured all necessary regulatory approvals to acquire Arcellx.
  • The Australian Competition and Consumer Commission (ACCC) approved the acquisition, subject to a 14-day review period.
  • Gilead has extended the tender offer for Arcellx shares to April 27, 2026.
  • As of April 16, 2026, approximately 17.5% of Arcellx shares have been validly tendered.

The big picture

Gilead's acquisition of Arcellx represents a significant bet on the emerging field of cell and gene therapy, a sector attracting substantial investment as potential cures for previously intractable diseases. The deal, valued at approximately $22 billion, underscores Gilead's strategic shift towards expanding its oncology pipeline beyond its core HIV and hepatitis franchises. The contingent value right (CVR) structure tied to anito-cel sales introduces a layer of complexity, aligning Gilead's incentives with Arcellx's commercial success.

What we're watching

Shareholder Sentiment
The remaining shareholder tender rate will be critical; a low rate could force Gilead to pursue alternative acquisition strategies or renegotiate terms.
Regulatory Risk
While the ACCC has approved the deal, potential challenges or further scrutiny from other regulatory bodies could still arise, impacting the timeline and ultimate success of the acquisition.
Integration Execution
Gilead's ability to successfully integrate Arcellx's gene therapy platform and pipeline will be key to realizing the anticipated strategic benefits and justifying the acquisition price.

Gilead Secures $1B+ Investment for Lenacapavir HIV Prevention Expansion

Event summary

  • PEPFAR, The Global Fund, and the U.S. State Department are jointly investing additional capital in Gilead’s lenacapavir, an injectable HIV prevention medication.
  • The total commitment now reaches $3 billion, aiming to expand access to lenacapavir for 3 million people in high-incidence, resource-limited countries by 2028.
  • Lenacapavir, approved in the US, reached sub-Saharan Africa in late 2025, a faster timeline than typical drug rollouts.
  • Gilead is providing lenacapavir at no profit to PEPFAR and The Global Fund and expects generic rollout to begin in 2027.

The big picture

This investment underscores the ongoing need for innovative HIV prevention strategies in resource-limited settings, where access to traditional PrEP remains a challenge. Gilead’s strategy of partnering with established global health organizations and facilitating generic manufacturing represents a shift towards broader access models, potentially reducing reliance on direct sales and expanding its social impact. The $3 billion commitment highlights the significant financial resources being deployed to combat the HIV epidemic, even as a cure remains elusive.

What we're watching

Generic Competition
The 2027 generic rollout will be a key inflection point, potentially impacting Gilead’s pricing power and market share in affected regions. Success will depend on Gilead’s voluntary licensing agreements and the generic manufacturers’ ability to scale production.
Distribution Logistics
The effectiveness of PEPFAR and The Global Fund’s distribution networks will be critical to achieving the stated reach of 3 million people, and any bottlenecks could delay impact and create reputational risk.
Adherence Risk
Given the twice-yearly injection schedule, patient adherence will be a significant factor in the program’s success, and Gilead will need to monitor and address any barriers to compliance.

Gilead Bolsters Oncology Pipeline with $3.15B Tubulis Acquisition

Event summary

  • Gilead Sciences has agreed to acquire Tubulis GmbH, a German biotechnology company, for $3.15 billion upfront, with up to $1.85 billion in contingent milestone payments.
  • The acquisition focuses on expanding Gilead’s antibody-drug conjugate (ADC) capabilities, including Tubulis’ lead asset, TUB-040, in Phase 1b/2 trials for ovarian cancer and NSCLC.
  • Tubulis’ ADC platform utilizes a next-generation conjugation technology and targets NaPi2b and 5T4, with TUB-030 demonstrating early clinical promise across solid tumors.
  • The deal is expected to close in Q2 2026 and will be financed through cash on hand and senior unsecured notes.
  • Tubulis will operate as a dedicated ADC research organization within Gilead, with its Munich site serving as a hub for ADC innovation.

The big picture

Gilead’s acquisition of Tubulis underscores the ongoing consolidation within the oncology space, as large pharmaceutical companies seek to bolster their pipelines with innovative ADC technologies. The $3.15 billion price tag reflects the growing value placed on targeted therapies and the potential for ADCs to address unmet needs in difficult-to-treat cancers. This move signals Gilead's continued commitment to oncology, following recent acquisitions of Arcellx and Ouro, and aims to position the company as a leader in next-generation cancer treatments.

What we're watching

Clinical Progress
The success of TUB-040 and TUB-030 in ongoing clinical trials will be critical in validating Gilead’s investment and demonstrating the platform’s efficacy, particularly given the challenging indications targeted.
Integration Risk
The integration of Tubulis’ Munich-based operations and ADC expertise into Gilead’s existing structure could face challenges, potentially impacting innovation speed and efficiency.
Competitive Landscape
The ADC market is increasingly competitive; Gilead’s ability to differentiate its portfolio and secure market share will depend on the unique advantages of Tubulis’ technology and pipeline.

Gilead Extends Arcellx Tender Offer, Faces Regulatory Hurdles

Event summary

  • Gilead Sciences has extended its tender offer to acquire Arcellx, pushing the expiration date to April 24, 2026.
  • The offer price remains at $115 per share plus a contingent value right (CVR) potentially worth $5 per share, payable in 2030 if sales exceed $6 billion.
  • As of March 31, 2026, approximately 7.5% of Arcellx’s outstanding shares (4,389,763 shares) have been validly tendered.
  • The acquisition is anticipated to close in Q2 2026, contingent on regulatory approvals and tender of a majority of Arcellx shares.

The big picture

Gilead's acquisition of Arcellx, valued at approximately $22.35 billion including the CVR potential, represents a strategic move to bolster its oncology pipeline, particularly in cell therapies. The CVR structure is a common tactic to bridge valuation gaps in acquisitions of biotech companies with unproven commercial products. The extension of the tender offer signals potential complexities in securing shareholder approval and navigating regulatory hurdles, typical of larger biopharma M&A deals.

What we're watching

Regulatory Headwinds
The extension suggests potential challenges in securing regulatory approvals, which could delay or impact the acquisition's finalization.
Sales Performance
Arcellx's ability to achieve the $6 billion sales threshold by 2029 will directly determine whether CVR holders receive the $5 payment, impacting the overall deal value.
Shareholder Acceptance
The low tender rate so far indicates potential resistance from Arcellx shareholders, and Gilead will need to incentivize further participation to secure a majority stake.

Gilead Acquires Ouro Medicines for $1.675 Billion, Bolsters Autoimmune Pipeline

Event summary

  • Gilead Sciences has agreed to acquire Ouro Medicines for $1.675 billion upfront, with up to $500 million in contingent milestone payments.
  • The acquisition brings OM336 (gamgertamig), a BCMAxCD3 T cell engager, into Gilead’s inflammation portfolio, targeting autoimmune diseases like AIHA and ITP.
  • OM336 has demonstrated efficacy in Phase 1/2 trials and is on track to enter registrational studies in 2027.
  • Gilead is in advanced discussions with Galapagos for a collaborative R&D agreement, with Galapagos absorbing Ouro’s assets and sharing development costs.
  • Keymed Biosciences retains commercialization rights for OM336 in Greater China.

The big picture

Gilead's acquisition of Ouro Medicines represents a significant bet on T cell engager therapies for autoimmune diseases, a market increasingly attractive as existing treatments often fail to provide long-term relief. The $1.675 billion price tag underscores the perceived value of this novel approach, but also creates pressure for rapid clinical success. The collaboration with Galapagos suggests a shared risk/reward model, reflecting the inherent uncertainties in developing first-in-class therapies.

What we're watching

Regulatory Risk
The success of OM336 hinges on FDA approval, and the Fast Track/Orphan Drug designations, while positive, don't guarantee a favorable outcome, especially given the novel mechanism of action.
Collaboration Dynamics
The Galapagos collaboration structure, with shared costs and royalties, will be critical to monitor; any disagreements or performance gaps could impact OM336’s development timeline and cost profile.
Clinical Efficacy
While early data is promising, the registrational trials will need to convincingly demonstrate durable remission and a differentiated safety profile compared to existing therapies to justify the acquisition price.

Gilead Foundation Invests $12 Million in Community HIV Prevention

Event summary

  • The Gilead Foundation committed $12 million to 33 community-based organizations across 14 states and D.C.
  • The two-year initiative focuses on expanding Community Health Worker (CHW)-led HIV prevention models.
  • Funding aims to strengthen organizational infrastructure, CHW training, and culturally responsive care within vulnerable communities.
  • Recipient organizations prioritize communities disproportionately affected by HIV, including MSM, transgender women, and people who inject drugs.

The big picture

Gilead's foundation investment reflects a growing trend among biopharmaceutical companies to address the social determinants of health, recognizing that medical innovation alone is insufficient to combat epidemics like HIV. This $12 million commitment, while substantial, represents a small fraction of Gilead’s overall revenue and underscores the company’s strategic focus on community-led solutions to complement its drug development efforts. The initiative's success will be a key indicator of Gilead's broader commitment to social responsibility and its ability to influence health equity outcomes.

What we're watching

Program Efficacy
The initiative's success hinges on the ability of grantees to demonstrably reduce HIV incidence and improve health outcomes within targeted communities, requiring rigorous data collection and analysis.
Sustainability
The long-term impact will depend on whether the strengthened CHW networks and organizational infrastructure can be sustained beyond the initial two-year grant period, necessitating diversified funding sources.
Regulatory Landscape
Changes in federal or state funding for public health programs could significantly impact the grantees' ability to continue their work, requiring Gilead to adapt its support strategies.

Gilead Data Shows Promise for Bictegravir/Lenacapavir Switch in HIV Treatment

Event summary

  • Phase 3 ARTISTRY-1 and ARTISTRY-2 trials demonstrated the efficacy of Gilead’s single-tablet regimen of bictegravir (75mg) and lenacapavir (50mg) (BIC/LEN) in patients switching from existing HIV therapies.
  • BIC/LEN showed non-inferiority to complex multi-tablet regimens and Gilead’s BIKTARVY® in maintaining virological suppression through Week 48.
  • The switch to BIC/LEN was associated with improvements in fasting lipid parameters and increased patient-reported treatment satisfaction.
  • Data was presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2026 and published in The Lancet on February 25, 2026.

The big picture

Gilead's ARTISTRY trials highlight the ongoing need for improved HIV treatment options, particularly for patients experiencing intolerance or drug interactions with existing regimens. The data suggests BIC/LEN could offer a compelling alternative, potentially expanding Gilead’s market share within the $30 billion HIV therapeutics market. The combination’s novel mechanism of action, targeting the capsid protein, represents a strategic diversification of Gilead’s HIV portfolio beyond integrase inhibitors.

What we're watching

Regulatory Approval
The speed with which regulatory authorities review and potentially approve BIC/LEN will dictate the timeline for its market entry and impact Gilead’s revenue projections.
Market Adoption
How quickly physicians and patients adopt BIC/LEN as a switch option, particularly given the established efficacy and familiarity with BIKTARVY, will be crucial for its commercial success.
Resistance Profile
Continued monitoring of the emergence of resistance to lenacapavir, despite the current data showing no resistance, will be essential to ensure the long-term durability of the treatment.

Gilead Advances HIV Treatment Pipeline with Novel Combination Regimens

Event summary

  • Gilead will present new data at CROI 2026 (Feb 22-25) focusing on expanding HIV treatment and prevention options.
  • Phase 3 trials (ARTISTRY-1 and ARTISTRY-2) explored bictegravir and lenacapavir combination for virologically suppressed patients.
  • Research includes a potential weekly oral HIV treatment regimen (islatravir plus lenacapavir) and a twice-yearly treatment option (teropavimab and zinlirvimab with lenacapavir).
  • Gilead is also advancing HIV cure research, including a program in South Africa involving cisgender women.

The big picture

Gilead's focus on expanding treatment options and exploring long-acting regimens reflects the ongoing effort to simplify HIV management and improve patient adherence. The ARTISTRY trials and other research represent a significant investment in a market estimated to be worth billions annually, but face increasing competition and the need for sustained clinical and regulatory success. The company's commitment to HIV cure research, while longer-term, underscores its broader strategic goal of ultimately eradicating the virus.

What we're watching

Regulatory Approval
The success of these novel regimens hinges on FDA approval, which will depend on the full dataset presented at CROI and subsequent regulatory reviews; delays or limitations could impact Gilead's market positioning.
Adoption Rates
The uptake of long-acting injectable therapies will be critical for Gilead's revenue projections, and will depend on patient and physician acceptance, as well as reimbursement coverage.
Competitive Landscape
Other pharmaceutical companies are also developing long-acting HIV therapies, and Gilead's ability to maintain a competitive edge will depend on demonstrating superior efficacy, safety, and convenience.

Gilead Boosts Dividend as Investment Strategy Faces Scrutiny

Event summary

  • Gilead Sciences increased its quarterly cash dividend by 3.8%, to $0.82 per share.
  • The dividend increase is effective in the first quarter of 2026 and will be paid on March 30, 2026.
  • The move follows a $32 billion investment announced in 2025 to strengthen Gilead’s U.S. footprint.
  • Gilead operates in over 35 countries and focuses on therapies for HIV, hepatitis, COVID-19, cancer, and inflammation.

The big picture

Gilead’s dividend increase signals a commitment to returning capital to shareholders, but arrives as the company navigates a period of significant investment in its U.S. infrastructure. This move may be intended to appease investors while the company’s large-scale investments mature, but the sustainability of the dividend hinges on Gilead’s ability to generate substantial returns from its expanded operations and pipeline. The decision also highlights the ongoing tension between rewarding existing shareholders and reinvesting in future growth within the biopharmaceutical sector.

What we're watching

Investment Impact
The dividend increase must be weighed against the substantial $32 billion investment in U.S. infrastructure; the returns from this investment will be crucial to sustaining the dividend and funding future growth.
Growth Pipeline
The company's ability to generate new revenue streams from its pipeline of therapies will determine whether it can maintain this dividend level and continue to invest in expansion.
Shareholder Pressure
Continued pressure from activist investors regarding capital allocation and the balance between dividends and R&D spending could influence future dividend decisions.

Gilead to Address Investors at J.P. Morgan Healthcare Conference

Event summary

  • Gilead Sciences executives will present at the J.P. Morgan Healthcare Conference on January 12, 2026.
  • The presentation will begin at 11:15 a.m. Pacific Time.
  • A live webcast will be available at investors.gilead.com, with a replay accessible for at least 30 days.
  • The conference is a major annual gathering for healthcare investors and industry leaders.

The big picture

The J.P. Morgan Healthcare Conference is a crucial event for biopharmaceutical companies to engage with investors and shape market perception. Gilead’s participation signals a continued effort to communicate its strategic direction amidst ongoing challenges related to patent expirations and evolving competitive dynamics within the $500+ billion global biopharmaceutical market. The conference provides a platform to address investor concerns and highlight potential growth drivers.

What we're watching

Pipeline Progress
The conference presentation will likely focus on Gilead’s pipeline, particularly its oncology and inflammation programs, and investors will scrutinize the data presented for signs of accelerated development or potential setbacks.
Competitive Landscape
Given the increasing competition in Gilead’s core therapeutic areas, the presentation will be assessed for how the company plans to maintain market share and defend its intellectual property.
Financial Outlook
The market will be looking for indications of how Gilead intends to navigate potential revenue declines from existing products and whether the company will outline specific strategies for future growth and profitability.

Gilead Exercises Option on Assembly Bio's Herpes Programs, Signals Pipeline Shift

Event summary

  • Gilead Sciences has exercised its option to license Assembly Biosciences’ helicase-primase inhibitor programs (ABI-1179 and ABI-5366) for recurrent genital herpes.
  • Gilead will pay Assembly Bio $35 million, reflecting a $45 million option fee, with $10 million already credited from prior funding.
  • Assembly Bio is eligible for up to $330 million in regulatory and commercial milestones and tiered royalties.
  • The deal represents the first program advanced under a 2023 R&D collaboration between the two companies.
  • ABI-1179 and ABI-5366 have shown promising Phase 1b data, demonstrating antiviral activity and potential for once-weekly oral dosing.

The big picture

Gilead's move underscores its ongoing strategy to bolster its antiviral pipeline through external collaborations, particularly in areas with unmet medical needs. The deal, valued at $35 million upfront with a potential $330 million in milestones, highlights the continued interest in novel therapies for recurrent genital herpes, a chronic condition affecting millions. This acquisition also signals a potential shift in Gilead’s development focus towards long-acting oral therapies, a trend gaining traction in the antiviral space.

What we're watching

Clinical Trial
The success of ABI-1179 and ABI-5366 will hinge on Phase 2/3 trial results, given the lack of new HSV therapies in over two decades; failure to demonstrate efficacy could significantly impact Gilead's antiviral pipeline strategy.
Financial Impact
Assembly Bio’s ability to secure and manage the $330 million in potential milestone payments will be crucial for its continued operations and pipeline development, especially given the option to share costs and profits.
Strategic Alignment
How Gilead integrates these programs into its existing antiviral portfolio and prioritizes their development relative to other pipeline assets will reveal the company’s long-term commitment to the HSV therapeutic area.

Gilead Agrees to Pricing Controls in Deal with U.S. Government

Event summary

  • Gilead Sciences has entered a three-year agreement with the U.S. government to lower drug costs for American patients.
  • The agreement mandates discounts on existing medications (HIV, Hepatitis C, Hepatitis B, COVID-19) for U.S. Medicaid, aligning prices with those in other developed nations.
  • Gilead will launch a Direct-to-Patient Program for Epclusa® via TrumpRx.gov, offering a discounted cash price.
  • Gilead receives a three-year exemption from Section 232 pharmaceutical tariffs contingent on increased U.S. manufacturing investment.
  • The company anticipates a manageable financial impact in 2026 and beyond, with additional terms remaining confidential.

The big picture

This agreement represents a significant shift in the U.S. government’s approach to drug pricing, potentially setting a precedent for future negotiations with pharmaceutical companies. It also underscores the growing pressure on biopharma firms to balance innovation with affordability, particularly as government intervention in healthcare pricing intensifies. Gilead’s $32 billion investment in U.S. manufacturing suggests a strategic response to these pressures, aiming to secure favorable regulatory treatment and bolster domestic production.

What we're watching

Financial Impact
The 'manageable' financial impact claim requires scrutiny; the undisclosed terms of the agreement could significantly alter Gilead’s revenue projections and profitability.
Patient Adoption
The success of the Direct-to-Patient Program hinges on patient awareness and willingness to utilize TrumpRx.gov, which may be a barrier to widespread adoption.
Tariff Dependency
Gilead’s continued exemption from Section 232 tariffs is tied to manufacturing investment; failure to meet those commitments could trigger renewed tariffs and impact production costs.

Gilead: Bictegravir/Lenacapavir Combo Shows Non-Inferiority in HIV Switch Trial

Event summary

  • Gilead’s Phase 3 ARTISTRY-2 trial demonstrated its investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) was non-inferior to BIKTARVY in virologically suppressed HIV patients.
  • The trial, completed in December 2025, evaluated a 2:1 switch from BIKTARVY to BIC/LEN, with the primary endpoint assessed at Week 48.
  • Topline results from ARTISTRY-1, announced in November 2025, also showed BIC/LEN to be well-tolerated and non-inferior to multi-tablet regimens.
  • BIC/LEN combines bictegravir (an integrase strand transfer inhibitor) with lenacapavir (a first-in-class capsid inhibitor).

The big picture

Gilead’s ARTISTRY trials represent a continued effort to refine HIV treatment regimens, focusing on simplified dosing and novel mechanisms of action. The non-inferiority result for BIC/LEN, while not a blockbuster outcome, expands Gilead’s portfolio and provides an alternative for patients already on BIKTARVY. This development underscores the ongoing evolution of HIV therapeutics, moving towards more patient-friendly and potentially curative approaches, though Gilead's dominance in the space faces increasing competition.

What we're watching

Regulatory Approval
The combined ARTISTRY-1 and ARTISTRY-2 data will be submitted for regulatory approval, and the speed of this process will dictate the timeline for potential market entry and revenue generation.
Market Adoption
The success of BIC/LEN will depend on physician and patient adoption, which will be influenced by factors such as pricing, reimbursement, and perceived benefits over existing therapies.
Long-Acting Potential
Gilead’s ongoing development of lenacapavir as a long-acting option could significantly alter the HIV treatment landscape, potentially cannibalizing demand for BIC/LEN and requiring a strategic shift in product positioning.
CID: 282